Investigation of factors which are related to urinary volume change after canagliflozin administration - Investigation of factors which are related to urinary volume change after canagliflozin administration

Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center0 个研究点目标入组 12 人开始时间: 2015年10月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients who have not received treatment of type 2 diabetes mellitus(diet therapy, exercise therapy, oral hypoglycemic agent and so on) 2. Patient with type 1 diabetes mellitus or with history of secondary diabetes mellitus 3. Patients who have experienced repeated severe hypoglycemic episodes 4. Patients with the history of serious diabetic complications requiring treatment 5. Patients treated with insulin, GLP-1 receptor agonist, SGLT-2 inhibitor, diuretic (including drug combination) 6. Patients with history of , or concurrent complication that affect renal function(renal disease, renal stone, prostatic inflammation and so on) , or patients with urinary-tract infection 7. Patients with history of drug or food allergies 8. Patients with history of myocardial infarction, congestive heart failure, unstable angina, cerebrovascular disease(except for lacunar infarction)within 6 months prior to screening visit (confirmation of eligibility) 9. Patients with history of TIA or cerebral infarction with clear neurological symptoms 10. Patients with peripheral arterial disease; Fontaine grade 3 or 4 11. Patients who correspond to contraindication or careful administration of canagliflozin (except for patient under treatment of hypoglycemic agents) 12. Patients with history of atrial fibrillation 13. Patients who are judged as inappropriate by investigators on screening examination.

发起方

Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center